Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Glaukos Corporation

< Previous 1 2 3 Next >
Glaukos Announces the Release of its 2021 Sustainability Report
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Executive Leadership Changes
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces FDA 510(k) Clearance of iPRIME™
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces Third Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces Second Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces First Quarter 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.